Chugai Pharma Valuation Multiples

Chugai Pharma Overview

About Chugai Pharma

Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan’s oncology market for the past decade, largely due to drugs licensed from its parent’s portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and Actemra for treating rheumatoid arthritis and covid patients.

Founded

1943

HQ

Employees

7.8K

Website

chugai-pharm.co.jp

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $8B

EBITDA: $4B

EV

$100B

Valuation Multiples

Multiples.vc

Start free trial

Chugai Pharma Financials

Chugai Pharma reported last 12-month revenue of $8B and EBITDA of $4B.

In the same LTM period, Chugai Pharma generated $6B in gross profit, $4B in EBITDA, and $3B in net income.

Chugai Pharma P&L

In the most recent fiscal year, Chugai Pharma reported revenue of $7B and EBITDA of $3B.

Chugai Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

Chugai Pharma Stock Performance

Chugai Pharma has current market cap of $106B, and enterprise value of $100B.

Chugai Pharma's stock price is $64.40.

Chugai Pharma Valuation Multiples

Chugai Pharma trades at 12.1x EV/Revenue multiple, and 23.8x EV/EBITDA.

Chugai Pharma Financial Valuation Multiples

As of March 7, 2026, Chugai Pharma has market cap of $106B and EV of $100B.

Equity research analysts estimate Chugai Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Chugai Pharma has a P/E ratio of 36.8x.

Chugai Pharma Margins & Growth Rates

Chugai Pharma's revenue in the last 12 month grew by 6%.

Chugai Pharma's revenue per employee in the last FY averaged $1.1M.

Chugai Pharma's rule of 40 is 57% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Chugai Pharma's rule of X is 66% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Chugai Pharma Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Chugai Pharma M&A Activity

Chugai Pharma acquired XXX companies to date.

Last acquisition by Chugai Pharma was on XXXXXXXX, XXXXX. Chugai Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Chugai Pharma Investment Activity

Chugai Pharma invested in XXX companies to date.

Chugai Pharma made its latest investment on XXXXXXXX, XXXXX. Chugai Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).